Condition: Bladder Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Munson Medical Center ( Site 0812) | Traverse City, Michigan, United States | Recruiting |
| TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822) | Cincinnati, Ohio, United States | Recruiting |
| The West Clinic, P.C. ( Site 0791) | Germantown, Tennessee, United States | Recruiting |
| Thompson Cancer Survival Center ( Site 0803) | Knoxville, Tennessee, United States | Recruiting |
| Asociacion de Beneficencia Hospital Sirio Libanes ( Site 0003) | Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Instituto Alexander Fleming ( Site 0002) | Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
| Instituto de Oncologia de Rosario ( Site 0005) | Rosario, Santa Fe Province, Argentina | Recruiting |
| Macquarie University ( Site 0031) | Macquarie, New South Wales, Australia | Recruiting |
| Mater Hospital Brisbane ( Site 0032) | South Brisbane, Queensland, Australia | Recruiting |
| Cliniques Universitaires Saint-Luc ( Site 0062) | Brussels, Bruxelles-Capitale, Region de, Belgium | Recruiting |
| AZ Maria Middelares ( Site 0063) | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
| UZ Gent ( Site 0064) | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07419295